Last week, a clinical trial that Emory researchers participated in was presented at the 2015 American Heart Association Scientific Sessions. The presentation revealed that the world’s smallest, minimally invasive cardiac pacemaker — the Micra Transcatheter Pacing System (TPS) — was successfully implanted in nearly all of the patients participating in the international clinical trial. The study was also published in The New England Journal of Medicine.
The non-randomized clinical trial enrolled a total of 725 patients across 56 centers, including Emory. Results showed the Micra TPS, which is about the size of a large vitamin and weighs less than a small coin, was successfully implanted in 99.2 percent of all patients (719 of 725). The device also over exceeded its safety and effectiveness measures and approximately 96 percent of patients experienced no major complications, which is 51 percent fewer than the complication rate seen in patients with conventional pacing systems.
Emory Healthcare cardiologists were the first in Georgia, and among the first in the United States, to begin implanting the Micra TPS last year. Emory was the top enrolling U.S. site in the trial.
“We were pleased to participate in this important trial, as this will likely be the way pacemakers are implanted in the future,” says Emory site principle investigator Michael S. Lloyd, MD, associate professor of medicine, Emory University School of Medicine.
“The outstanding results are very encouraging and will allow us to continue to offer this novel device as a safe alternative to our patients.”
Dr. Lloyd, a cardiac electrophysiologist, implanted the first Micra TPS at Emory in April 2014 at Emory University Hospital. He says there are an estimated 3 million people living with pacemakers, and about 600,000 pacemakers are implanted in the world every year.
During the procedure, the tiny device — approximately one-tenth the size of a conventional pacemaker — is delivered through a catheter inserted in the femoral vein to the inside of the heart. Once positioned, it securely attaches to the endocardial tissue of the heart wall and sends electrical pulses to the heart through electrode tips whenever it senses an abnormal heart rhythm.
Unlike conventional pacemakers, the Micra TPS does not require the use of wires, known as “leads.” These leads, threaded through blood vessels to connect to the heart, are sometimes the source of serious medical complications such as infection and vein injury.
Another important difference between the new device and traditional pacemakers is that implantation of the Micra TPS does not require a surgical incision and the creation of a “pocket” under the skin. Conventional pacemakers require a more invasive surgery.
“By not creating a pocket and implanting a rigid device directly below the skin, it eliminates another potential source of complications and any visible sign of the device,” says cardiologist Mikhael El Chami, MD, associate professor of medicine, who is also implanting the Micra TPS device at Emory.
For more information on Micra TPS at Emory, please call 800-75-EMORY.
About Emory’s Arrhythmia Treatment Program
Emory’s arrhythmia treatment program is one of the most comprehensive and innovative clinics for heart rhythm disorders in the country. Emory’s electrophysiologists have been pioneers in shaping arrhythmia treatment options for patients with arrhythmias, such as atrial fibrillation, as well as for those with congestive heart failure. As primary and principal investigators for many national clinical trials, Emory has participated in numerous atrial fibrillation (A-fib, AF) and atrial flutter (a-flutter) studies with multiple catheters and energy sources. We are the only center in Georgia participating in a trial that provides alternatives to blood thinners to prevent stroke in patients with A-fib. We also have ongoing clinical trials of new pacemakers, defibrillators, ablation catheters, as well as new ways to use existing devices to help patients.